Differential Response and Resistance to KRAS‐Targeted Therapy
Sign Up to like & getrecommendations! Published in 2025 at "Molecular Carcinogenesis"
DOI: 10.1002/mc.23908
Abstract: KRAS is the most frequently mutated oncogene. In epithelial malignancies such as lung, colorectal, and pancreatic tumors, KRAS is mutated in 25 to above 90% cases. KRAS was considered undruggable for over three decades until… read more here.
Keywords: resistance; kras targeted; resistance kras; response ... See more keywords
Abstract 4984: Integrated platform enables KRAS-targeted drugs discovery
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-4984
Abstract: The Kirsten rat sarcoma viral oncogene homolog (KRAS) is mutated in approximately 25% of all human cancers and is known to be a major player promoting and maintaining tumorigenesis through the RAS-MAPK pathway. Activating mutations… read more here.
Keywords: kras g12c; integrated platform; kras targeted; platform enables ... See more keywords
Abstract PR09: KRAS-targeted PROTAC degraders are broadly efficacious against KRAS-dependent tumor models
Sign Up to like & getrecommendations! Published in 2023 at "Molecular Cancer Research"
DOI: 10.1158/1557-3125.ras23-pr09
Abstract: KRAS is genomically altered in about one third of all human tumors. Due to its central role in oncogenesis, many attempts have been made in the last four decades to drug mutant KRAS, either directly… read more here.
Keywords: kras dependent; targeted protac; mutant kras; kras targeted ... See more keywords